| Size | Price | Stock | Qty |
|---|---|---|---|
| 1mg |
|
||
| 5mg |
|
||
| Other Sizes |
| Targets |
Momordicin IV does not have a well-defined pharmacological target. As a natural product isolated from bitter melon, it is classified as a terpenoid. Bitter melon extracts and compounds have been studied for various biological activities including antidiabetic, anti-inflammatory, and anticancer effects. The specific targets of Momordicin IV require further investigation.
|
|---|---|
| ln Vitro |
In vitro activity data for Momordicin IV are limited. As a natural triterpenoid glycoside, it may exhibit biological activities similar to other compounds from bitter melon. Further studies are needed to characterize its specific in vitro activities, including potential effects on cell viability, inflammation, or glucose metabolism.
|
| ln Vivo |
In vivo activity data for Momordicin IV are limited. As a natural product, it may contribute to the traditional medicinal uses of bitter melon. No specific in vivo pharmacological data are available. Further studies are needed to determine its efficacy in animal models.
|
| Enzyme Assay |
The non-cellular assay for Momordicin IV involves standard chemical characterization to confirm its identity and purity. Techniques include HPLC, NMR, and mass spectrometry. Its amphipathic properties can be assessed by measuring solubility in various solvents. As a natural product, its purity and identity should be confirmed by comparison with authentic standards.
|
| Cell Assay |
In vitro cell-based assays for Momordicin IV would involve culturing relevant cell lines (e.g., cancer cells, pancreatic beta cells, immune cells) and treating with the compound. Cell viability is assessed using MTT or CellTiter-Glo assays. Anti-inflammatory activity can be assessed by measuring cytokine production. Antidiabetic effects can be evaluated by assessing glucose uptake or insulin secretion.
|
| Animal Protocol |
In vivo animal study protocols for Momordicin IV would involve disease models relevant to bitter melon's traditional uses, such as diabetic models or inflammation models. The compound is administered via appropriate routes. Endpoints include blood glucose levels, inflammatory markers, and tissue histology.
|
| ADME/Pharmacokinetics |
Pharmacokinetic properties of Momordicin IV are not characterized. As a triterpenoid glycoside with a molecular weight of 634.84, it is expected to have limited oral bioavailability. The compound should be stored at -20°C and protected from light.
|
| Toxicity/Toxicokinetics |
Toxicological data for Momordicin IV are limited. As a natural product, it is generally considered safe at moderate doses. Standard safety precautions should be observed during handling. The compound is for research use only and not for human use.
|
| References | |
| Additional Infomation |
Momordicin IV is a natural triterpenoid glycoside from bitter melon (Momordica charantia). It is used in biochemical research and is classified as a terpenoid. It is not a therapeutic drug and has no clinical trial or marketing authorization status.
|
| Molecular Formula |
C36H58O9
|
|---|---|
| Molecular Weight |
634.84
|
| Exact Mass |
634.408
|
| CAS # |
894412-35-2
|
| PubChem CID |
162861131
|
| Appearance |
Typically exists as solids at room temperature
|
| Density |
1.24±0.1 g/cm3(Predicted)
|
| Boiling Point |
760.1±60.0 °C(Predicted)
|
| LogP |
0
|
| Hydrogen Bond Donor Count |
6
|
| Hydrogen Bond Acceptor Count |
9
|
| Rotatable Bond Count |
8
|
| Heavy Atom Count |
45
|
| Complexity |
1160
|
| Defined Atom Stereocenter Count |
15
|
| SMILES |
[#6]-[#6](-[#6]-[#6](-[#8])\[#6]=[#6](\[#6])-[#6])-[#6]1-[#6]-[#6]C2([#6])[#6]3-[#6](-[#8]-[#6]-4-[#8]-[#6](-[#6]-[#8])-[#6](-[#8])-[#6](-[#8])-[#6]-4-[#8])-[#6]=[#6]4-[#6](-[#6]-[#6]-[#6](-[#8])C4([#6])[#6])C3([#6]-[#6]C12[#6])[#6]=O |c:29|
|
| InChi Key |
OGYOYYHXZZLIRV-ODMNCKKZSA-N
|
| InChi Code |
InChI=1S/C36H58O9/c1-19(2)14-21(39)15-20(3)22-10-11-35(7)31-25(44-32-30(43)29(42)28(41)26(17-37)45-32)16-24-23(8-9-27(40)33(24,4)5)36(31,18-38)13-12-34(22,35)6/h14,16,18,20-23,25-32,37,39-43H,8-13,15,17H2,1-7H3/t20-,21+,22-,23-,25+,26-,27+,28-,29+,30-,31+,32-,34-,35+,36-/m1/s1
|
| Chemical Name |
(3S,7S,8S,9R,10R,13R,14S,17R)-3-hydroxy-17-[(2R,4R)-4-hydroxy-6-methylhept-5-en-2-yl]-4,4,13,14-tetramethyl-7-[(2R,3R,4S,5S,6R)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy-2,3,7,8,10,11,12,15,16,17-decahydro-1H-cyclopenta[a]phenanthrene-9-carbaldehyde
|
| Synonyms |
Momordica charantia IV
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
May dissolve in DMSO (in most cases), if not, try other solvents such as H2O, Ethanol, or DMF with a minute amount of products to avoid loss of samples
|
|---|---|
| Solubility (In Vivo) |
Note: Listed below are some common formulations that may be used to formulate products with low water solubility (e.g. < 1 mg/mL), you may test these formulations using a minute amount of products to avoid loss of samples.
Injection Formulations
Injection Formulation 1: DMSO : Tween 80： Saline = 10 : 5 : 85 (i.e. 100 μL DMSO stock solution → 50 μL Tween 80 → 850 μL Saline)(e.g. IP/IV/IM/SC) *Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH ₂ O to obtain a clear solution. Injection Formulation 2: DMSO : PEG300 ：Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL DMSO → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline) Injection Formulation 3: DMSO : Corn oil = 10 : 90 (i.e. 100 μL DMSO → 900 μL Corn oil) Example: Take the Injection Formulation 3 (DMSO : Corn oil = 10 : 90) as an example, if 1 mL of 2.5 mg/mL working solution is to be prepared, you can take 100 μL 25 mg/mL DMSO stock solution and add to 900 μL corn oil, mix well to obtain a clear or suspension solution (2.5 mg/mL, ready for use in animals). View More
Injection Formulation 4: DMSO : 20% SBE-β-CD in saline = 10 : 90 [i.e. 100 μL DMSO → 900 μL (20% SBE-β-CD in saline)] Oral Formulations
Oral Formulation 1: Suspend in 0.5% CMC Na (carboxymethylcellulose sodium) Oral Formulation 2: Suspend in 0.5% Carboxymethyl cellulose Example: Take the Oral Formulation 1 (Suspend in 0.5% CMC Na) as an example, if 100 mL of 2.5 mg/mL working solution is to be prepared, you can first prepare 0.5% CMC Na solution by measuring 0.5 g CMC Na and dissolve it in 100 mL ddH2O to obtain a clear solution; then add 250 mg of the product to 100 mL 0.5% CMC Na solution, to make the suspension solution (2.5 mg/mL, ready for use in animals). View More
Oral Formulation 3: Dissolved in PEG400 (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 1.5752 mL | 7.8760 mL | 15.7520 mL | |
| 5 mM | 0.3150 mL | 1.5752 mL | 3.1504 mL | |
| 10 mM | 0.1575 mL | 0.7876 mL | 1.5752 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
